1. Scrip
  2. >>Business
  3. >>Earnings

Merck KGaA Well-Equipped Against War And Raw Material Shortages

Healthcare Sales Strong In Q1

 
• By Kevin Grogan

Despite the impact of the war in Ukraine and spiralling costs, as well as lower COVID-19-based revenues, the German group is forecasting a healthy financial performance for full-year 2022.

Belen Garijo
Belén Garijo • Source: Merck KGaA

Merck KGaA is well positioned to navigate the challenges thrown up by "a highly dynamic geopolitical situation," declared CEO Belén Garijo after presenting a solid set of financials for the first quarter.

Speaking to journalists as Merck posted a 12.2% in sales to €5.13bn, Garijo said the convergence of the pandemic and the war in Ukraine "has created a very challenging and volatile operating environment

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

Merck KGaA Braces For Volatility But Does Not Expect Europe To Budge On Pricing

 
• By Andrew McConaghie

Shares are hit as German conglomerate lowers revenue forecast.

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Cipla Leadership’s Early Take On Trump’s Pricing EO And Pipeline Progress

 
• By Anju Ghangurde

Cipla's CEO underlines that US generic prices are already “very significantly comparable” with the rest of the world and expects President Donald Trump's executive order on drug pricing to primarily impact branded pharmaceuticals. The company also shared updates on its US pipeline.